Zaburzenia poznawcze i neuropsychiatryczne w chorobie Parkinsona

Wallner, Renata; Senczyszyn, Adrianna; Budrewićz, Sławomir; Rymaszewska, Joanna

doi:10.5603/ppn.2019.0018

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parkinson's disease (PD) is a chronic, slowly progressive, neurodegenerative disease belonging to the group of alpha-synucleinopathy. [30] Worldwide, over 10 million people are affected, while in Europe the prevalence and incidence are estimated at approximately 108-257/100,000 and 11-19/100,000 per year, respectively. [3], [7] PD affects 1-2% of the population of people over 65 years of age and may increase up to 4% among people over 85 years of age, which confirms the fact that the main risk factor for the development of the disease is old age, because cells show a greater degree of dysfunction during aging.…”

Section: Introductionmentioning

confidence: 99%

“…[3] PD is associated with the loss of dopaminergic neurons, initially the dorsal nucleus of the vagus nerve and the olfactory bulb, then the locus coeruleus, and finally involving the substantia nigra. [20], [30] The extensive process of creating new neuronal processes of nigrostriatal dopaminergic neurons increases their energy demand and affects proteostasis and lysosomal functions. The loss of dopaminergic neurons in familial forms of the disease is associated with mutations in the SNCA, Parkin/PARK2, UCHL1, PINK1, DJ-1/PARK7, and LRRK2 genes.…”

Section: Introductionmentioning

confidence: 99%

“…They include α-synuclein and cell membrane components. [2], [30] Various mechanisms at the cellular and molecular level also underlie the disease, including oxidative stress, mitochondrial dysfunction, proteostasis and neuroinflammation. [2] Environmental risk factors for the development of the disease include alcohol, tobacco and exposure to vitamin D. Research indicates that, however, they have a smaller role in the pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

“…Their presence in these areas is responsible for vegetative symptoms in people with PD. [30] Currently available therapies provide good control of motor symptoms but do not modify the development of the disease. [3] Due to the increasing number of patients in Poland, work is underway to introduce comprehensive, coordinated care for patients with Parkinson's disease.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Parkinson's Disease - A Review of Diagnostic Methods and Modern Therapies

Borowska-Waniak,

Marcinkiewicz,

Ochotnicka

et al. 2024

ArveMED

View full text Add to dashboard Cite

Parkinson's disease (PD) is a chronic, neurodegenerative disease belonging to the group of alpha-synucleinopathies. It is associated with the loss of dopaminergic neurons and is characterized by the presence of Lewy bodies. The diagnosis of PD is mainly based on the clinical picture. The basis of therapy are dopaminergic drugs, and the doses of drugs, as well as the frequency of their administration, should be increased along with the progression of the disease, which, however, is associated with an increase in side effects. We are still looking for new solutions that will make the therapy optimal and tailored to each patient. Currently, methods such as deep brain stimulation are becoming more and more available. New technologies such as PD-watch, hydrogel, Parkinson's gloves, STAT-ON TM or gene therapy bring hope to patients struggling with this disease on a daily basis. The aim of our work was to provide an overview of modern treatment methods and to provide the reader with basic information about Parkinson's disease. The information we used in this work comes from a critical review of the Pubmed literature, as well as specialized medical literature. Methods:We analyzed scientific publications containing information on Parkinson's disease, current treatment data. We also searched for modern diagnostic methods and information on Parkinson's disease treatment options. We have collected the data and summarized it in this article. Conclusion: Currently available therapies provide good control of motor symptoms, but do not modify the development of Parkinson's disease. However, the development of technology and medicine allows us to think that in the future the fate of patients with this disease will change, and new solutions will bring positive results.

show abstract

Section: Introductionmentioning

confidence: 99%